Galmed Reports Breakthrough in MASH Treatment

Galmed Pharmaceuticals (GLMD) has released an update.

Galmed Pharmaceuticals has published promising one-year results of the ARCON Phase 3 trial in Hepatology, demonstrating the significant anti-fibrotic effects of Aramchol, a treatment for metabolic dysfunction associated steatohepatitis (MASH). The study, which included 150 patients with NASH and fibrosis, used a combination of traditional and AI digital pathology to validate its findings, positioning Aramchol as a potent anti-fibrotic agent in the MASH treatment landscape. The company’s commitment to combination therapy and Aramchol’s unique action mechanism sets it apart in the competitive field of liver and metabolic disease treatments.

For further insights into GLMD stock, check out TipRanks’ Stock Analysis page.